exRNAdisease

Entry Detail

---



General Information

Database ID: exR0087775 RNA Name: hsa-miR-144-3p RNA Type: miRNA Chromosome: chr17 Starnd: - Coordinate: Start Site(bp): 28861548 End Site(bp): 28861567 External Links: hsa-miR-144-3p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand ANXA2 chr15 60347134 60402883 - ARHGAP18 chr6 129576132 129710177 - CNOT11 chr2 101252886 101270316 + EPHA7 chr6 93240020 93419559 - G3BP2 chr4 75642782 75724525 - GABPB1 chr15 50275392 50355408 - IKZF2 chr2 212999691 213152427 - RAB15 chr14 64945814 64973226 - ROCK2 chr2 11179759 11348330 - SGPP1 chr14 63684216 63728065 - USP47 chr11 11841423 11961887 + ZNF695 chr1 246945547 247008093 - miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0001376 chr3 194169185 194175121 - lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC010980.2 chr2 222317242 222318653 - AC022167.2 chr16 8848105 8860456 + AC093010.3 chr3 114314501 114329714 - AF254983.1 chr21 10482738 10605716 + ARHGAP27P1-BPTFP1-KPNA2P3 chr17 64749663 64781707 - EBLN3P chr9 37079645 37090928 + HCG11 chr6 26521709 26527404 + LINC00662 chr19 27681072 27794005 - MALAT1 chr11 65497688 65506516 + NEAT1 chr11 65422774 65445540 + NORAD chr20 36045618 36051018 - OTUD6B-AS1 chr8 91059318 91070583 - SDCBP2-AS1 chr20 1325405 1378735 + TUG1 chr22 30969245 30979395 + XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.